COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Total Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Total Liabilities
$18.8m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Theratechnologies Inc
TSX:TH
Total Liabilities
$79.2m
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
13%
Repare Therapeutics Inc
NASDAQ:RPTX
Total Liabilities
$11.6m
CAGR 3-Years
-52%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Liabilities
$161.8m
CAGR 3-Years
36%
CAGR 5-Years
30%
CAGR 10-Years
27%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Total Liabilities
$48.3m
CAGR 3-Years
29%
CAGR 5-Years
23%
CAGR 10-Years
24%
Spectral Medical Inc
TSX:EDT
Total Liabilities
CA$76.8m
CAGR 3-Years
118%
CAGR 5-Years
55%
CAGR 10-Years
39%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Total Liabilities?
Total Liabilities
18.8m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Total Liabilities amounts to 18.8m USD.

What is COSCIENS Biopharma Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
-6%

Over the last year, the Total Liabilities growth was -21%. The average annual Total Liabilities growth rates for COSCIENS Biopharma Inc have been 3% over the past three years , 2% over the past five years , and -6% over the past ten years .

Back to Top